 Shares of Blueprint Medicines Corp NASDAQ:BPMC have earned an average recommendation of Buy from the sixteen analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have assigned a buy rating and one has given a strong ... 